BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Aging
    • Alzheimer's disease
    • Biosimilars
      • Artificial intelligence
    • Coronavirus
    • Infographics: Dynamic digital data analysis
    • Israel
    • IVDs on the rise
    • Radiopharmaceuticals
    • Rise of obesity
    • Top Biopharma Trends of 2023
    • Top Med-tech Trends of 2023
    • Top Preclinical Trends of 2023
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • sign in
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, April 10, 2024
See today's BioWorld MedTechSee today's BioWorld
Home » Thiel calls for improving research grant, regulatory processes to enhance scientific innovation
X
/images/Cortellis_Flagship_Logo_TM_RGB_Color.png

Upgrade your daily dose of biopharma and medtech news

Subscribe to BioWorld™ news services

See subscription options
To read the full article sign up for free or sign in.
Precision Medicine World Conference

Thiel calls for improving research grant, regulatory processes to enhance scientific innovation

Jan. 22, 2020
By Stacy Lawrence
No Comments
SANTA CLARA, Calif. – Peter Thiel is not a fan of incremental science. The high-profile venture capital investor, who invests across technology and the life sciences via various vehicles, including the Founders Fund, suggested that as academic and government bureaucracies have scaled up and rigidified over the last 50 or 60 years, that has eroded the ability of researchers to pursue innovative science.
BioWorld BioWorld MedTech Conferences U.S.

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for April 9, 2024.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for April 9, 2024.
  • Illustration of amyloid plaques in Alzheimer's disease

    After the first approvals, where does amyloid go from here?

    BioWorld
    After decades of trying and dozens of failed trials, amyloid targeting has paid off with the first disease-modifying agents reaching the market. But success does...
  • Post-J&J bid, Sensei explores new oncology VISTAs

    BioWorld
    An increasingly popular target across varied cancer types is the immune system regulator V-domain Ig suppressor of T-cell activation (VISTA), where a number of...
  • Black and white arrows merging into one

    Labcorp to pay Opko $237.5M for select Bioreference assets

    BioWorld MedTech
    Laboratory Corporation of America Holdings Inc. agreed to purchase select assets of Bioreference Health from Opko Health Inc. for $237.5 million in a deal slated...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2024. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing